Abstract
In response to the outbreak of SARS-CoV-2 many governments decided in 2020 to impose lockdowns on societies. Although the package of measures which constitute such lockdowns differs between countries, it is a general rule that contacts between people, and especially in large groups of people, are avoided or prohibited. The main reasoning behind these measures is preventing that healthcare systems become overloaded. As of 2021 vaccines against SARS-CoV-are available, but these do not guarantee 100% risk reduction and it will take a while for the world to reach a sufficient immune status. This raises the question whether and under which conditions events like theater shows, conferences, professional sports events, concerts and festivals can be organized. The current paper presents a COVID-19 Risk taxation method for (large scale) events. This method can be applied to events to define an alternative package of measures replacing generic social distancing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Click NL, see https://www.clicknl.nl/en/about-clicknl/
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Ethics Committee TU Delft (http://hrec.tudelft.nl/) The application is approved by the Ethics Committee on the 4 December 2020. Contact persons: Ir. J.B.J. Groot Kormelink, secretary HREC Dr. Ir. U. Pesch Chair HREC Faculty of Technology, Policy and Management.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We added the reduction of infectiousness and susceptibility because of vaccination and an earlier infection to the model.
Data Availability
All data produced in the present work are contained in the manuscript
